We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Part of AbbVie, Inc.
Clinical Trials
1741
1522 active
Approvals
118
Total approvals
Agencies
6
Regulatory bodies
Founded
N/A
Recruiting
156
9.0%
Withdrawn
9
0.5%
Active, not recruiting
1519
87.3%
Completed
54
3.1%
Not yet recruiting
3
0.2%
NMPA
National Medical Products Administration
17
EMA
European Medicines Agency
40
PHILIPPINES
Philippines FDA
SFDA
Saudi Food and Drug Authority
2
NPRA
National Pharmaceutical Regulatory Agency
4
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
52
- AbbVie Deutschland GmbH & Co. KG is conducting two separate first-in-human Phase 1 studies evaluating ABBV-525, a MALT1 inhibitor, and ABBV-101, a BTK degrader, for relapsed/refractory B-cell non-Hodgkin's lymphoma. - ABBV-525 targets the MALT1 protein that helps cancer cells survive and grow, while ABBV-101 represents a novel BTK degrader approach that removes BTK proteins rather than simply inhibiting them. - The ABBV-525 study will enroll approximately 150 participants worldwide over 64 months, while the ABBV-101 study will include approximately 188 patients over 60 months. - Both oral therapies aim to address unmet medical needs for patients whose B-cell malignancies have relapsed or become refractory to current treatments.
